Engot-Ov44/First Study: A Randomized, Double-Blind, Adaptive, Phase Iii Study Of Standard Of Care (Soc) Platinum-Based Therapy +/- Dostarlimab Followed By Niraparib +/- Dostarlimab Maintenance As First-Line (1l) Treatment Of Stage 3 Or 4 Ovarian Cancer (Oc).

Anne-Claire Hardy-Bessard,Kathleen N. Moore,Mansoor Raza Mirza,Bernard Asselain,Andres Redondo, Jacobus Pfisterer,Sandro Pignata,Diane M. Provencher,David Cibula, Anna K.L. Reyners,Lubomir Bodnar,Rosalind Glasspool,Christos Papadimitriou, Rami Eitan,Sileny N. Han,Linda R. Duska,BJ Rimel,Gupta Divya,Jian Chen,Eric Pujade-Lauraine

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 9|浏览1

暂无评分

摘要

TPS6101Background: Despite surgery and CT (paclitaxel + carboplatin ± bevacizumab [bev]), 5-year survival rates remain low for patients (pts) with FIGO stage 3 or 4 OC. Niraparib is a poly (ADP-rib...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要